The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, open-label, phase 2b study of the BET bromodomain inhibitor (BETi) ZEN-3694 plus enzalutamide vs. enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).
 
Rahul Aggarwal
Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; Curio Science; EcoR1 Capital; Exelixis; Flare Therapeutics; Guidepoint Inc; Harpoon therapeutics; Janssen; Merck; MJH Life Sciences; Novartis; PCCTC; Pfizer; Research to Practice; Slingshot Insights; Tersera; Washington Research Foundation
Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
Expert Testimony - University of Utah Health
Travel, Accommodations, Expenses - DAVA Oncology
 
Michael Schweizer
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; FibroGen; Janssen; Pfizer; Sanofi
Research Funding - Ambrx (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Epigenetix (Inst); Immunomedics (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SignalOne Bio (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenith Epigenetics (Inst)
 
Christopher Chay
No Relationships to Disclose
 
Omkar Marathe
Employment - The Oncology Institute of Hope and Innovation
Leadership - Clinical trial director; Clinical trial director
Stock and Other Ownership Interests - Anixa Biosciences; ImmunityBio; Nektar; SpringWorks Therapeutics; Summit Therapeutics; Syndax; The Oncology Institute of Hope and Innovation
 
Emilio Araujo-Mino
No Relationships to Disclose
 
David Morris
Stock and Other Ownership Interests - UROGPO
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Clovis Oncology; Decipher Biosciences; Dendreon; Janssen Oncology; Lantheus Medical Imaging; Merck Serono; Myovant Sciences; Myriad Genetics; Pfizer/EMD Serono; Tolmar; Urogen pharma; UROGPO
Speakers' Bureau - Astellas Medivation; AstraZeneca; Janssen; Merck; Pfizer/Astellas
Research Funding - Astellas Pharma (Inst); AstraZeneca/Merck (Inst); Bayer (Inst); Clovis Oncology (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer/Astellas (Inst); Urogen pharma (Inst)
 
David Nanus
Honoraria - Genentech
Consulting or Advisory Role - AstraZeneca; Janssen Scientific Affairs
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Exelixis (Inst); immumedics (Inst); Janssen (Inst); Novartis (Inst); pfizer (Inst); Sagimet Biosciences (Inst); Zenith Epigenetics (Inst)
 
Mohit Narang
Consulting or Advisory Role - Celgene
Speakers' Bureau - Celgene
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Ian Schnadig
Employment - Compass Oncology
Leadership - Compass Oncology
 
Sarah Attwell
Employment - Zenith Epigenetics
Stock and Other Ownership Interests - Zenith Epigenetics
Patents, Royalties, Other Intellectual Property - Zenith Epigenetics patent for the use of ZEN003694 in prostate cancer
 
Emily Johnson
Employment - Zenith Epigenetics
Stock and Other Ownership Interests - Zenith Epigenetics
 
Philip Wegge
Employment - Zenith Epigenetics
Stock and Other Ownership Interests - Zenith Epigenetics
 
Vandy Xu
Employment - Newsoara Biopharma
Stock and Other Ownership Interests - Newsoara Biopharma
Travel, Accommodations, Expenses - Newsoara Biopharma
 
Helena Zhu
Employment - Newsoara Biopharma
Stock and Other Ownership Interests - Newsoara Biopharma
Travel, Accommodations, Expenses - Newsoara Biopharma
 
Alissa McGuire
No Relationships to Disclose
 
Margo Snyder
Employment - Zenith Epigenetics
Stock and Other Ownership Interests - Zenith Epigenetics
Travel, Accommodations, Expenses - Zenith Epigenetics
 
Michael Sweeney
Employment - Zenith Epigenetics Corp
Leadership - Resverlogix corp
Stock and Other Ownership Interests - Resverlogix corp; Zenith Epigenetics Corp
 
Sanjay Lakhotia
Employment - Zenith Epigenetics
Leadership - Zenith Epigenetics
Stock and Other Ownership Interests - Zenith Epigenetics
Travel, Accommodations, Expenses - Zenith Epigenetics
 
Joshi Alumkal
Consulting or Advisory Role - FibroGen; ORIC Pharmaceuticals
Research Funding - NCCN/Pfizer; Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - ORIC Pharmaceuticals